Compare Abbott Laboratories (ABT) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Tenet Healthcare Corporation — how do they compare? Abbott Laboratories trades at $95.2 (market cap $166.94B), while Tenet Healthcare Corporation trades at $206.32 (market cap $17.76B). The key difference: Abbott Laboratories is far larger — about 9.4× Tenet Healthcare Corporation's market cap, and Abbott Laboratories pays a 2.63% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals.
| ABT | THC | |
|---|---|---|
Market Cap | $166.94B | $17.76B |
Sector | Health | Health |
52-Week High | $136.62 | $244.80 |
52-Week Low | $82.57 | $148.38 |
Enterprise Value | $193.69B | $28.00B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Tenet Healthcare (THC) trades at $206.19, up 1.21% today, with a bullish technical outlook supported by moving averages and strong analyst sentiment. The stock shows robust fundamentals with a P/E of 10.72, net income margin of 7.79%, and consistent earnings beats in recent quarters. Recent news highlights growth in outpatient care and positive market performance amid broader dips.
Outlook remains positive with an 81.25% analyst buy rating and $233.38 consensus price target, though overbought RSI signals near-term caution. Risks include healthcare regulatory pressures and debt levels, but expanding admissions and solid cash flow support long-term upside for value and growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
